Enhance genius behind the genes.
Latest News
August 10th, 2016 – CarthaGenetics appoints new International Medical Director in Germany
Australian biotech
innovator race
Oncology signs
agreement with
CarthaGenetics for EU
market development of
chemotherapy
drug Bisantrene
CarthaGenetics® announced today that it had signed an agreement with the Australian company race Oncology to expedite the launch of the company’s Named Patient Program (NPP) in Europe, and to distribute and sell Bisantrene under the program. Under the agreement, CarthaGenetics® will be responsible for market development and awareness of Bisantrene prior to launch and all necessary regulatory approvals to allow Bisantrene to be sold in each target NPP country. CarthaGenetics® will also be responsible for all storage, distribution, invoicing, sales and customer service of Bisantrene in each country under the Named Patient Program. CarthaGenetics® Founder and CEO, Philippe Carteron de Balmont, said: “At CarthaGenetics, we are proud to help Race Oncology launch Bisantrene and achieve success in the European market. Named Patient access regulations in individual European countries allow patients access to innovative therapies under development. Given Bisantrene’s safety profile and clinical data, it is well-suited to a Named Patient sales Program in those countries”. The agreement will also provide Race with all the infrastructure and logistical support needed to sell Bisantrene in various European countries. In all markets outside Europe, Race Oncology is now actively pursuing licensees for Bisantrene. “CarthaGenetics are experts in Named Patient Program sales in Europe,” said Managing Director, Peter Molloy. “Their expertise will help ensure Bisantrene gets to market rapidly and achieves its full sales potential.” To that end, both companies will be attending the BioPharm America conference in Boston on 13-15 September, 2016. For more information, contact: phcarteron@carthagenetics.com
Latest Events
October 4th , 2016 – Meet CarthaGenetics at CPHI Worldwide 2016
CarthaGenetics® will be attending CPHI Worldwide 2016 Congress in Barcelona, Spain from October 4th-6th, 2016. If you would like to arrange a meeting with us during the conference, please contact Philippe Carteron de Balmont, CEO, at: phcarteron@carthagenetics.com
September 28th, 2016 – Meet CarthaGenetics at BioSpain 2016
CarthaGenetics® will be attending the BioSpain 2016 Congress in Bilbao, Spain, from September 28th-30th, 2016. If you would like to arrange a meeting with us during the conference, please contact Naciba Zetchi, Area Director, Spain and Portugal, at: Zetchi@carthagenetics.com
